Daniel Kulick
Family Medicine · Brown City, MINPI 1720206600
Payments from drug & device makers
Across 138 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$448
- AstraZeneca$410
- Novo Nordisk$191
- Merck$185
- Lilly USA, LLC$160
- Bayer$126
- plus $718 from 14 others
What the payments were for
- Food & beverage$2,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $448 |
| AstraZeneca | 25 | $410 |
| Novo Nordisk | 13 | $191 |
| Merck | 11 | $185 |
| Lilly USA, LLC | 8 | $160 |
| Bayer | 8 | $126 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Exact Sciences | 5 | $95 |
| Mylan Specialty L.p. | 5 | $88 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Johnson & Johnson | 3 | $62 |
| Boehringer Ingelheim | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Boston Scientific | 1 | $42 |
| GSK | 2 | $40 |
| Pfizer | 2 | $37 |
| Optinose US, Inc. | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
How this compares
$2,238 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $26,888 |
| MounjaroTirzepatide | 16 | $23,154 |
| TrulicityDulaglutide | 15 | $22,017 |
| XareltoRivaroxaban | 20 | $20,202 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $17,471 |
| EliquisApixaban | 17 | $10,378 |
| LinzessLinaclotide | 13 | $6,817 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $6,376 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,254 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,223 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,205 |
| Atorvastatin Calcium | 135 | $1,949 |
| Methadone Hcl | 47 | $1,873 |
| Telmisartan | 48 | $1,627 |
| Lisinopril | 152 | $1,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $160 | $45,17131 claims |
| GSKTrelegy Ellipta | $40 | $26,88826 claims |
| Johnson & JohnsonXarelto | $62 | $20,20220 claims |
| PfizerEliquis | $37 | $10,37817 claims |
| AbbVieLinzess | $448 | $6,81713 claims |
| AstraZenecaSymbicort | $410 | $3,22313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Brown City
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.